Is atopy a risk indicator of chronic obstructive pulmonary disease in dairy farmers?

Affiliation auteurs!!!! Error affiliation !!!!
TitreIs atopy a risk indicator of chronic obstructive pulmonary disease in dairy farmers?
Type de publicationJournal Article
Year of Publication2019
AuteursVeil-Picard M, Soumagne T, Vongthilath R, Annesi-Maesano I, Guillien A, Laurent L, Andujar P, Roche N, Jouneau S, Cypriani B, Laplante J-J, Degano B, Dalphin J-C
JournalRESPIRATORY RESEARCH
Volume20
Pagination124
Date PublishedJUN 17
Type of ArticleArticle
ISSN1465-993X
Mots-clésAtopy, chronic obstructive pulmonary disease, Farmers, Matthieu Veil-Picard and Thibaud Soumagne contributed equally to the work, Occupational Exposure, Specific IgE
Résumé

Allergic mechanisms related to environmental and occupational exposure have been suggested to contribute to the development of chronic obstructive pulmonary disease (COPD).ObjectivesTo investigate the relationships between atopy markers, persistent airflow limitation (PAL) and occupational exposure in dairy farmers.MethodsClinical and biological (total IgE and 21 allergen specific IgE) markers of atopy were assessed in 101 dairy farmers with PAL (DF-PAL), 85 non-farmers with PAL (NF-PAL) (both groups were prospectively included from a screening program performed between 2011 and 2015), and matched controls, i.e. 98 farmers without PAL (DF-controls) and 89 non-farming subjects without PAL (NF-controls). Occupational exposure in farmers was estimated using a validated questionnaire.ResultsPrevalence of allergy history was significantly higher in DF-PAL and in NF-PAL than in controls. Polysensitization, and sensitization to seasonal and food allergens were more frequent in DF-PAL than in DF-controls, respectively: 13.8% vs 1% (adjusted odds ratio (aOR): 17.5 (2.2-134), 11.9% vs 3.1% (aOR: 4.4 (1.2-7.2) and 16.8% vs 4.1% (aOR: 5.2 (1.7-7.2)). The prevalence of atopy markers was similar between NF-PAL patients and NF-controls.ConclusionsPAL in farmers is associated with a high rate of markers of atopy, supporting atopy as a risk indicator.Clinical trial registered with ClinicalTrials.gov (NCT02540408).

DOI10.1186/s12931-019-1082-2